β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction

Charbel Abi Khalil, Mohammad Zubaid, Nidal Asaad, Wafa A. Rashed, Adel Khalifa Hamad, Rajvir Singh, Jassim Al Suwaidi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The benefits of β-blockers in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) are controversial. The Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department (ED). We studied the incidence of 6- and 12-month mortality, hospitalization for HF or AF, and stroke/transient ischemic attacks (TIAs) in patients with HFrEF, in relation to β-blockers on discharge from the ED or the subsequent hospital stay. Of the 344 patients with HFrEF and AF in the GULF-SAFE, 177 patients (53%) were discharged on β-blockers. Mortality was lower in those patients compared with the non-β-blockers group at 6 and 12 months (odds ratios [ORs] 0.31, 95% CI [0.16-0.61]; OR 0.30, 95% CI [0.16-0.55]; P =.001 for both, respectively), so was the risk of stroke/TIAs. However, hospitalizations for AF increased in the β-blockers group. Even after adjustment for several risk variables in 2 different models, the beneficial effect of β-blockers on mortality persisted, at the cost of more hospitalization for AF.

Original languageEnglish
Pages (from-to)316-322
Number of pages7
JournalAngiology
Volume69
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Fingerprint

Atrial Fibrillation
Heart Failure
Stroke
Mortality
Hospitalization
Transient Ischemic Attack
Hospital Emergency Service
Odds Ratio
Risk Adjustment
Registries
Length of Stay
Incidence

Keywords

  • atrial fibrillation
  • cardiovascular mortality
  • heart failure
  • stroke
  • β-blockers

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction. / Abi Khalil, Charbel; Zubaid, Mohammad; Asaad, Nidal; Rashed, Wafa A.; Hamad, Adel Khalifa; Singh, Rajvir; Al Suwaidi, Jassim.

In: Angiology, Vol. 69, No. 4, 01.04.2018, p. 316-322.

Research output: Contribution to journalArticle

Abi Khalil, Charbel ; Zubaid, Mohammad ; Asaad, Nidal ; Rashed, Wafa A. ; Hamad, Adel Khalifa ; Singh, Rajvir ; Al Suwaidi, Jassim. / β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction. In: Angiology. 2018 ; Vol. 69, No. 4. pp. 316-322.
@article{deeec90ff70047219cd30013c1f452c0,
title = "β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction",
abstract = "The benefits of β-blockers in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) are controversial. The Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department (ED). We studied the incidence of 6- and 12-month mortality, hospitalization for HF or AF, and stroke/transient ischemic attacks (TIAs) in patients with HFrEF, in relation to β-blockers on discharge from the ED or the subsequent hospital stay. Of the 344 patients with HFrEF and AF in the GULF-SAFE, 177 patients (53{\%}) were discharged on β-blockers. Mortality was lower in those patients compared with the non-β-blockers group at 6 and 12 months (odds ratios [ORs] 0.31, 95{\%} CI [0.16-0.61]; OR 0.30, 95{\%} CI [0.16-0.55]; P =.001 for both, respectively), so was the risk of stroke/TIAs. However, hospitalizations for AF increased in the β-blockers group. Even after adjustment for several risk variables in 2 different models, the beneficial effect of β-blockers on mortality persisted, at the cost of more hospitalization for AF.",
keywords = "atrial fibrillation, cardiovascular mortality, heart failure, stroke, β-blockers",
author = "{Abi Khalil}, Charbel and Mohammad Zubaid and Nidal Asaad and Rashed, {Wafa A.} and Hamad, {Adel Khalifa} and Rajvir Singh and {Al Suwaidi}, Jassim",
year = "2018",
month = "4",
day = "1",
doi = "10.1177/0003319717722283",
language = "English",
volume = "69",
pages = "316--322",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction

AU - Abi Khalil, Charbel

AU - Zubaid, Mohammad

AU - Asaad, Nidal

AU - Rashed, Wafa A.

AU - Hamad, Adel Khalifa

AU - Singh, Rajvir

AU - Al Suwaidi, Jassim

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The benefits of β-blockers in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) are controversial. The Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department (ED). We studied the incidence of 6- and 12-month mortality, hospitalization for HF or AF, and stroke/transient ischemic attacks (TIAs) in patients with HFrEF, in relation to β-blockers on discharge from the ED or the subsequent hospital stay. Of the 344 patients with HFrEF and AF in the GULF-SAFE, 177 patients (53%) were discharged on β-blockers. Mortality was lower in those patients compared with the non-β-blockers group at 6 and 12 months (odds ratios [ORs] 0.31, 95% CI [0.16-0.61]; OR 0.30, 95% CI [0.16-0.55]; P =.001 for both, respectively), so was the risk of stroke/TIAs. However, hospitalizations for AF increased in the β-blockers group. Even after adjustment for several risk variables in 2 different models, the beneficial effect of β-blockers on mortality persisted, at the cost of more hospitalization for AF.

AB - The benefits of β-blockers in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) are controversial. The Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department (ED). We studied the incidence of 6- and 12-month mortality, hospitalization for HF or AF, and stroke/transient ischemic attacks (TIAs) in patients with HFrEF, in relation to β-blockers on discharge from the ED or the subsequent hospital stay. Of the 344 patients with HFrEF and AF in the GULF-SAFE, 177 patients (53%) were discharged on β-blockers. Mortality was lower in those patients compared with the non-β-blockers group at 6 and 12 months (odds ratios [ORs] 0.31, 95% CI [0.16-0.61]; OR 0.30, 95% CI [0.16-0.55]; P =.001 for both, respectively), so was the risk of stroke/TIAs. However, hospitalizations for AF increased in the β-blockers group. Even after adjustment for several risk variables in 2 different models, the beneficial effect of β-blockers on mortality persisted, at the cost of more hospitalization for AF.

KW - atrial fibrillation

KW - cardiovascular mortality

KW - heart failure

KW - stroke

KW - β-blockers

UR - http://www.scopus.com/inward/record.url?scp=85042796968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042796968&partnerID=8YFLogxK

U2 - 10.1177/0003319717722283

DO - 10.1177/0003319717722283

M3 - Article

VL - 69

SP - 316

EP - 322

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 4

ER -